drugset / Trial / NCT05414032
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
Phase 2
Recruiting
102 enrolled
University Health Network, Toronto
AstraZeneca · collabNeoGenomics Laboratories, Inc. · collabPersonalis Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally advanced head and neck squamous cell carcinoma (LA-HNSCC). MRD is defined as ctDNA detection in plasma after definitive treatment. Approximately 100 patients are expected to be enrolled.
Timeline
- Start
- 2023-07-12
- Primary completion
- 2027-09
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rilvegostomig | Other / unclassified | 750 mg | Intravenous |